Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Infographics

Future Truths: Inevitable and Inspiring

The current supply of inpatient beds is far higher than what we need now, or even what we'll need a decade from now.

Partner, Health and Life Sciences, Oliver Wyman
Engagement Manager, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Oliver Wyman Actuarial Consulting

Summary of CY2022 Advance Notice Summary Part II

CMS proposes Stars rating changes, revises MA plan definitions, calls for new COVID-19 vaccination measures, and more.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting
Senior Consultant, Oliver Wyman
Senior Consultant, Oliver Wyman
Senior Consultant, Oliver Wyman

The current supply of inpatient beds is far higher than what we need now, or even what we'll need a decade from now.

Partner, Health and Life Sciences, Oliver Wyman
Engagement Manager, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Oliver Wyman Actuarial Consulting

How Market Trends and Dynamics are Impacting Insurers' Bottom Lines

An analysis of market profitability and capitalization trends as well as new insights into insurers' recent claims experiences.

Principal, Actuarial, Oliver Wyman
Senior Consultant, Oliver Wyman
Senior Consultant, Oliver Wyman

Part 4: State-by-State Market Impact

Six factors that dictate the kind of health coverage people who've lost their jobs want next.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Oliver Wyman Actuarial Consulting
Senior Consultant, Oliver Wyman

Insights in your inbox

Subscribe

Healthcare Cost and Utilization During COVID-19

An analysis of what claim payments and delays may look like later this year.

Practice Leader, Oliver Wyman Actuarial Consulting
Principal, Actuarial, Oliver Wyman

An analysis of annual premiums by federal poverty level.

Practice Leader, Oliver Wyman Actuarial Consulting

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

Why a focus on the provider is needed to achieve 4 or 5 Stars.

Principal, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Based on our analysis recently featured in the Wall Street Journal, the prevalence of no cost bronze coverage has increased significantly for 2018.

Principal, Oliver Wyman Actuarial Consulting
Practice Leader, Oliver Wyman Actuarial Consulting

Insights in your inbox

Subscribe